共 489 条
[1]
Younossi ZM(2016)Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 73-84
[2]
Koenig AB(2022)Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Clin Mol Hepatol 28 841-850
[3]
Abdelatif D(2018)Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68 335-352
[4]
Fazel Y(2010)Epidemiology of non-alcoholic fatty liver disease Dig Dis 28 155-161
[5]
Henry L(2020)Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study Sci Rep 10 21117-72
[6]
Wymer M(2022)NAFLD in normal weight individuals Diabetol Metab Syndr 14 45-299
[7]
Le MH(2019)Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality Clin Diabetes 37 65-1763
[8]
Yeo YH(2022)Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease Gut Liver 16 290-G411
[9]
Zou B(2019)Mechanistic links between obesity, diabetes, and blood pressure: role of perivascular adipose tissue Physiol Rev 99 1701-357
[10]
Barnet S(2020)Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodeling: findings from the community-based Framingham Heart Study PLoS ONE 15 G400-3109